Chlamydia Disease

Published Date : Sep 2023
Category : Infectious Diseases
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

Chlamydia - A Holistic Landscape Overview by DiseaseLandscape Insights

Chlamydia is a common sexually transmitted infection (STI) that is gaining attention due to its quick global spread. The causes of this infection have increased due to numerous changing behaviors and inadequate awareness among people. Due to its weak symptoms, this STI frequently goes unrecognized, but the effects are severe.

Disease Overview -

The bacterium Chlamydia Trachomatis causes a Chlamydia infection. Chlamydia is habitually referred to as a “silent” infection. Most people with the infection have no indications. CDC studies estimate that about 10% of men and 5-30% of women with a confirmed infection develop symptoms. Chlamydia infections spread to other areas including the anus, lymph nodes and eyes, throat.

In women, the bacteria initially infect the cervix. This causes signs and symptoms of cervicitis, infection spreads from the cervix to the upper reproductive tract (i.e., uterus, fallopian tubes), causing Pelvic Inflammatory Disease (PID).

Men with Chlamydia infection symptoms often develop urethritis, which is characterized by dysuria and a mucoid or watery urethral discharge. Some men experience unilateral testicular pain, sensitivity, and swelling due to epididymitis. Both men and women get chlamydia in the rectum. Chlamydia if left untreated raises the risk of contracting or transmitting HIV.

Lymphogranuloma Venereum (LGV) is type of STD caused by C. trachomatis. Spread of LGV infections leads to proctitis outbreaks among gay, bisexual, and other men who have sex with men (MSM).

According to the WHO reports, in 2022, chlamydia affected about 129 million people globally and CDC reports have shown, in 2021, that there were nearly 1.6 million cases of chlamydia reported in the United States making it a dominant region for Chlamydia cases.   It has become a major concern for the healthcare industry since it is difficult to control and manage cases of chlamydia.

In 2021, chlamydia cases for African and Black Americans were six times more than that of Whites. Chlamydia is also common among MSM. Chlamydia is transmitted by oral, vaginal, or anal contact with an infected person. During childbirth, pregnant women transmit chlamydia to their newborn children. Some infants develop conjunctivitis or pneumonia as a result of this.

Chlamydia is most common among young people, and infected people with this infection show no symptoms and therefore get neglected. Two-thirds of new chlamydial infections occur among young people from age 15-24 years. According to reports, 1 in 20 sexually active young women have chlamydia infection.

Young persons who engage in sexual activity have a significant chance of getting chlamydia due to behavioral, biological, and cultural factors. This increases the risk of transmission. High chlamydia prevalence among young people also reflects barriers to accessing STD prevention services.

Proactive measures, testing, and treatments are essential to limit Chlamydia's impact and safeguard the public's health as it spreads.

Diagnostic Analysis -

Transformative Approaches to Chlamydia Testing:

Understanding the most recent developments and trends in diagnostics of chlamydia infection enables businesses to create groundbreaking products, increase customer trust, and grab untapped market opportunities.

According to the CDC, one in five Americans is diagnosed with sexually transmitted infections every year, which is why access to faster diagnostic results and, more appropriate treatments make significant strides in combatting these infections.

In 2019, the U.S. Food and Drug Administration approved two tests for marketing that detected the presence of the bacteria Chlamydia trachomatis.

So, the following are some diagnostic techniques listed to detect chlamydia infection which is already being used in the market

  1. Nucleic Acid Amplification Tests (NAATs):

    NAATs are highly sensitive and specific molecular tests that detect the genetic material (DNA or RNA) of Chlamydia trachomatis. These tests are performed on urine samples, swabs from the genital or rectal areas, and in some cases, throat swabs.

National Institute of Allergy and Infectious Diseases evaluated the diagnostic accuracy of multiple commercially available nucleic acid amplification tests for the detection of Chlamydia trachomatis from throat and rectal sites. The results of this study showed that the Aptima Combo 2 Assay and the Xpert CT/NG are safe and effective.

  1. Enzyme Immunoassays (EIAs):

    EIAs detect the presence of Chlamydia-specific antigens or antibodies in a patient's body fluids. They are less sensitive than NAATs but are still widely used due to their convenience.
  2. Direct Fluorescent Antibody (DFA) Tests:

    DFA tests use fluorescent-labeled antibodies that specifically bind to Chlamydia antigens in patient samples. They are used for identifying Chlamydia in samples taken from genital, rectal, or ocular sites.
  3. Nucleic Acid Hybridization Tests:

    These tests detect the presence of Chlamydia DNA or RNA by hybridizing labeled probes to the target genetic material. They are less commonly used compared to NAATs.
  4. Point-of-Care Tests (POCT):

    These are rapid diagnostic tests that provide results on the spot. These tests use NAATs or other techniques which are useful for immediate diagnosis. FDA announced in 2021 that they are allowing the use of the Binx Health IO CT/NG Assay at point-of-care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

To Unlock the Hidden Potential of The Diagnostic Market for Chlamydia, DLI Players Explore the Data-Rich Terrain to Extract Invaluable Insights. Collarbone with DLI for Understanding the Scope of Growth in this Ever-Expanding Chlamydia Diagnostic Market.

The following is a list of market enthusiasts whose ground-breaking diagnostic innovations are altering the healthcare sector:

                                                                                Diagnostic Market Players

NAAT (Nucleic Acid Amplification Tests)

ELISA Test kits

Point-of-care testing (POCT) devices

Abbott Laboratories

Abbott Laboratories


Hologic, Inc.


Abbott Laboratories

Roche Diagnostics


 Becton, Dickinson, and Company


Focus Diagnostics (DiaSorin Group)

Hologic, Inc.

Bio-Rad Laboratories, Inc

Thermo Fisher Scientific

Roche Diagnostics

DiaSorin Molecular LLC

Bio-Rad Laboratories


Gen-Probe Incorporated



Siemens Healthineers




                                                                                      Diagnostic Market Products

NAAT (Nucleic Acid Amplification Tests)

ELISA Test kits

Point-of-Care Testing (POCT) devices

Aptima Combo 2 Assay

ELx800 Universal Microplate Reader

GeneXpert System

cobas® CT/NG Test

Architect Chlamydia trachomatis IgG

ID NOW™ System (formerly Alere™ i)

BD ProbeTec™ Chlamydia trachomatis Qx Amplified DNA Assay

LIAISON Chlamydia trachomatis IgG

Sofia 2 Fluorescent Immunoassay Analyzer

Xpert® CT/NG

BioPlex 2200 Chlamydia IgG

Aptima Combo 2 Assay


Elecsys Anti-Chlamydia IgG

cobas Liat System


Treatment Analysis -

The Road to Chlamydia Recovery Towards Better Health.

Chlamydia is a sexually transmitted infection that requires effective treatment to prevent complications and adverse health complications and stop further sexual transmission. All people with chlamydial infection should receive treatment promptly, delays in treatment result in problems (such as PID in a small percentage of women)

The primary treatment approach for chlamydia involves the use of antibiotics. The following recommendations apply to adults, adolescents, and pregnant women suffering from Chlamydia. Specific recommendations are developed for Ophthalmia Neonatorum caused by C. trachomatis in infants.

  1. Antibiotics:

    Antibiotics are the cornerstone of Chlamydia treatment. The two main antibiotics used are Azithromycin and Doxycycline. These antibiotics target the Chlamydia bacteria, inhibiting their growth and effectively clearing the infection. The choice between Azithromycin and Doxycycline depends on factors such as patient preferences, medical history, and potential allergies.
  • Azithromycin:

Azithromycin is often prescribed as a single oral dose, making it convenient for patients. Its effectiveness in treating Chlamydia is well-documented. However, there have been concerns about antibiotic resistance, prompting the need for careful antibiotic stewardship to preserve its efficacy.

  • Doxycycline:

Doxycycline is taken as a course over a span of 7 days. It is highly effective against Chlamydia. While it requires a longer treatment duration compared to azithromycin, doxycycline remains a reliable option for patients who can tolerate the medication.

  • Recommended for Adolescents and Adults with Chlamydial Infection

The highly recommended drug to treat infection is Doxycycline 100 mg given orally 2 times/day for 7 days and alternative medications given to adults are Azithromycin 1 g orally in a single dose or Levofloxacin drug of 500 mg given orally daily for 7 days

Studies have also demonstrated that doxycycline drug is more efficacious for men and women than azithromycin drug

  • Recommended for Pregnant women with Chlamydial Infection

This drug Azithromycin 1 g is given orally in a single dose to infected women during pregnancy or Amoxicillin 500 mg an alternative drug given orally 3 times/day for 7 days. Amoxicillin is considered to be an alternative therapy for pregnant women affected by C. infection.

  • Recommendations for Neonates with Chlamydial Infection

Erythromycin base or ethylsuccinate 50 mg/ is given orally to infants, or azithromycin is divided into 4 doses daily for 14 days and is given to Neonates. Because the efficacy of erythromycin treatment for ophthalmia neonatorum is approximately 80%, a second course of therapy might be required for full recovery among neonates.

  1. Follow-Up Testing:

The majority of post-treatment infections do not result from treatment failure but rather from reinfection caused by the failure of sex partners to receive treatment or initiation of sexual activity with a newly infected partner. Repeat infections confer an elevated risk for PID and other complications among women. Therefore, it is important to take follow-up tests.

Follow-up testing after completing treatment is recommended to ensure that the infection has been successfully cleared. This step helps confirm treatment efficacy and prevent complications.

Treatment guidelines change over time due to evolving resistance patterns, emerging research, and advancements in medical knowledge. Regulatory Compliance becomes important to understand for treatment recommendations based on individual health factors and the latest medical guidelines. Additionally, the emergence of antibiotic-resistant strains highlights the importance of responsible antibiotic use and ongoing research to ensure effective Chlamydia treatment in the future.

DiseaseLandscape Insights supports the market participants to transform and expand in the treatment domain of Chlamydia infection in order to improve patient retention, explore innovations in the treatment area, and achieve new business heights.

DLI equips market players to be one step ahead of the competition with our detailed analysis of treatment options, service contributions, inventory of products, and market competition. The worldwide chlamydia disease diagnostic market is highly fragmented and owes a prominent market player with a global presence. 

The market leaders in the table below are reshaping the landscape and pushing innovation to achieve better health outcomes.

                                                                                Treatment Market Players








Johnson & Johnson

GlaxoSmithKline (GSK)

Teva Pharmaceutical

Teva Pharmaceutical


Daiichi Sankyo

Sun Pharmaceutical Industries


Sandoz (Novartis)

Watson Laboratories


Teva Pharmaceutical


Aurobindo Pharma

Teva Pharmaceutical


Dr. Reddy's Laboratories

Abbott Laboratories


Market Trend Analysis -

Chlamydia remains one of the most reported sexually transmitted infections globally, with increasing numbers of cases being diagnosed each year. The market trend is driven by a combination of factors, including improved testing, and reporting methods, changing sexual behaviors, and insufficient awareness about the infection. The growing rates of this disease are increasing the diagnostic needs and also developing the need for more advanced tests, which is raising the growth of the market.

However, healthcare organizations are placing greater emphasis on early detection and routine screening for Chlamydia. Increased awareness about the importance of regular STI testing is driving more people to seek testing services. There's a growing demand for convenient and rapid testing methods therefore FDA has approved Point-of-care testing for chlamydia and made it more prevalent to prevent complications and further transmission.

There are growing concerns about antibiotic-resistant strains of Chlamydia. This highlights the importance of appropriate and timely treatment to prevent the development of resistant strains. Additionally, research and development efforts are focused on improving testing accuracy, developing more effective treatments, and exploring potential vaccines.

Government programs are also fuelling the market's expansion. For instance, the UK government stated that the National Chlamydia Screening Programme (NCSP) will concentrate testing on women because they are most likely to experience catastrophic repercussions from the infection. This announcement was made in June 2021.

The program intends to extend testing for sexually active women in community settings and deliver treatment more quickly. Such efforts by various governments to lessen the impact of diseases and boost economic growth.

Regulatory Framework -

Recent updates in regulatory guidelines provided by DiseaseLandscape Insights services are immensely helpful for growing businesses. These updates verify that businesses stay in compliance with changing industry standards, navigate potential legal pitfalls, and streamline their product development and marketing processes.

Since high number of chlamydia infections has increased the need for NAAT testing, which has elevated the growth of the chlamydia infection. Thereby, increasing product approvals from authorities are driving the market growth.

  • For instance, the US Food and Drug Administration (FDA) said in March 2022 that the Binx Health IO CT/N test would be accepted at point-of-care locations in doctor's offices, community clinics, urgent care centers, and other end users. Product approvals have increased the prominence of the market within a population as individuals become more aware and purchase various products for the diagnosis of chlamydia infection.
  • The United States Food and Drug Administration also granted Visby Medical a waiver under the clinical laboratory improvement amendments of 1988 in August 2021, allowing it to sell its rapid PCR diagnostic test for the multiplexed detection of chlamydia.
  • Similarly, in May 2022, Abbott received FDA clearance for its Alinity m STI assay. A clinician or patient must collect one swab sample or one urine sample in a healthcare facility for the Alinity m STI for Chlamydia.

Competitive Analysis -

In order to increase the level of competition, a number of multinational industries are focusing on producing new products and improving the use of technology to improve existing operations. The focus of industries is also on ways to increase the number of products they sell, most frequently through partnerships, regulatory approval of medical research and technologies, and a focus on cooperation. Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, DiaSorin SpA, F Hoffmann-La-Roche Ltd, Hologic, and others are some of the major players in the market.

  • A completely automated, high-throughput infectious disease molecular diagnostics platform was introduced in the United States by Becton, Dickinson, and Company in May 2022. A new analytical instrument choice for the BD COR System is the BD COR MX instrument. The BD CTGCTV2 molecular assay, is a single test that identifies the three most common non-viral STDs, Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis.
  • As part of National STD Awareness Week in April 2022, the Chiricahua Community Health Centers, Inc. (CCHCI) announced a partnership with Visby Medical, Inc. and The Body Agency Collective (TBAC) to enhance the identification and treatment of sexually transmitted infections (STIs).
  • This project utilizes a new PCR diagnostic device which is the Sexual Health Click Test, and it detects three of the most common and curable STIs in women – gonorrhea, chlamydia, and trichomoniasis.

The market is now more aware of both diseases and the products that these businesses produce thanks to research and development. The production and sale of such products have enhanced the companies' overall revenue. However, it improved industry partnerships and set a new benchmark for other major firms.

DiseaseLandscape Insights assists the industry participant in choosing the best market to grow exponentially by offering in-depth knowledge about all the market participants currently active, their inventions, tactics, and collaborations.

Clinical Assessments-

DiseaseLandscape Insight Services provides comprehensive assistance in planning, carrying out, and assessing clinical studies for the development of novel medications as a committed partner to the pharmaceutical industry.

The analyses include all relevant information on the successes and failures of competing treatments in the market, similar drugs in developmental stages, and ongoing clinical studies. Currently, most of the ongoing trials are in Phase 2, 3 & 4.

The following table includes active clinical studies along with their titles, and stages.

Phase 2

Phase 3

Phase 4

Single Arm Trial of Menstrual Cups Among Economically Vulnerable Women to Reduce Bacterial Vaginosis and STIs Through Reduced Harmful Sexual and Menstrual Practices

Sanitation, Water, and Instruction in Face-washing for Trachoma I/II

Enhancing the A in SAFE: Accelerating Trachoma Elimination in the Republic of South Sudan

A Double-Masked, Placebo-Controlled, Randomized, Phase II Clinical Trial To Assess The Efficacy Of IVIEW-1201 In The Treatment Of Acute Adenoviral Conjunctivitis


Azithromycin Reduction to Reach Elimination of Trachoma



Kebele Elimination of Trachoma for Ocular Health



Chlamydia disease is becoming more common, which has led to an increase in the healthcare industry and a greater emphasis on early detection and preventative treatments. The industry is not only effectively responding to the growing trend but also establishing a holistic strategy to tackle this infection by prioritizing early diagnosis through better diagnostic technologies and investing in novel treatment methods. From diagnosis to treatment, this collaborative effort demonstrates the industry's commitment to better health outcomes and highlights its crucial role in establishing a future with lower Chlamydia prevalence.

DiseaseLandscape Insights (DLI) plays a crucial role in providing valuable information and comprehensive analysis of the Chlamydia disease healthcare market.

DLI Services helps market players, such as pharmaceutical companies and healthcare providers, identify potential areas for investment and research. By gaining an understanding of prevalent diseases and unmet medical needs.

DLI services aid in assessing the competitive landscape by highlighting existing treatments and therapies, allowing businesses to identify white spaces in the market where opportunities for innovation and market entry lie. Additionally, understanding disease dynamics helps businesses anticipate future market demands and make informed decisions about resource allocation, ultimately leading to more successful and impactful products and services in the healthcare industry.

In conclusion, DLI serves as a powerful tool for healthcare organizations to identify opportunities, analyze competition, and navigate the regulatory landscape effectively. By leveraging these insights, companies are making informed decisions, developing targeted therapies, and providing better healthcare solutions to meet the needs of patients and medical professionals a like.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape